inclusion criteria: 1. signed informed consent provided by the patient, or by the patient's legally authorized representative(s), as applicable. 2. documented presence of sars-cov-2 infection as per hospital routine. 3. age \> 18 to \< 85 years at the time of screening. 4. presence of respiratory distress, defined as: 1. pao2/fio2 \< 300 mm hg and \>200 mm hg or 2. respiratory rate (rr) ≥30 breaths/min or 3. spo2 \< 93 percent in air at rest. note: patients given continous positive airway pressure (cpap) ventilator support are eligible for inclusion. presence of hyperinflammation defined as: 1. lymphocyte counts: * \< 1000 cells/µl, in patients who have not received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count * \< 1200 cells/µl, in patients who have received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count and 2. one of the following three criteria: i. ferritin \> 500ng/ml ii. ldh \> 300 u/l iii. d-dimers \> 1000 ng/ml

inclusion criteria: 1. signed informed consent provided by the patient, or by the patient's legally authorized representative(s), as applicable. 2. documented presence of sars-cov-2 infection as per hospital routine. 3. age \> 18 to \< 85 years at the time of screening. 4. presence of respiratory distress, defined as: 1. pao2/fio2 \< 300 mm hg and \>200 mm hg or 2. respiratory rate (rr) ≥30 breaths/min or 3. spo2 \< 93 percent in air at rest. note: patients given continous positive airway pressure (cpap) ventilator support are eligible for inclusion. presence of hyperinflammation defined as: 1. lymphocyte counts: * \< 1000 cells/µl, in patients who have not received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count * \< 1200 cells/µl, in patients who have received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count and 2. one of the following three criteria: i. ferritin \> 500ng/ml ii. ldh \> 300 u/l iii. d-dimers \> 1000 ng/ml

inclusion criteria: signed informed consent provided by the patient, or by the patient's legally authorized representative(s), as applicable. documented presence of sars-cov-2 infection as per hospital routine. age > 18 to < 85 years at the time of screening. presence of respiratory distress, defined as: pao2/fio2 < 300 mm hg and >200 mm hg or respiratory rate (rr) ≥30 breaths/min or spo2 < 93 percent in air at rest. note: patients given continous positive airway pressure (cpap) ventilator support are eligible for inclusion. presence of hyperinflammation defined as: lymphocyte counts: < 1000 cells/µl, in patients who have not received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count < 1200 cells/µl, in patients who have received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count and one of the following three criteria: i. ferritin > 500ng/ml ii. ldh > 300 u/l iii. d-dimers > 1000 ng/ml

inclusion criteria: signed informed consent provided by the patient, or by the patient's legally authorized representative(s), as applicable. documented presence of sars-cov-2 infection as per hospital routine. age > 18 to < 85 years at the time of screening. presence of respiratory distress, defined as: pao2/fio2 < 300 mm hg and >200 mm hg or respiratory rate (rr) ≥30 breaths/min or spo2 < 93 percent in air at rest. note: patients given continous positive airway pressure (cpap) ventilator support are eligible for inclusion. presence of hyperinflammation defined as: lymphocyte counts: < 1000 cells/µl, in patients who have not received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count < 1200 cells/µl, in patients who have received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count and one of the following three criteria: i. ferritin > 500ng/ml ii. ldh > 300 u/l iii. d-dimers > 1000 ng/ml

inclusion criteria: 1. signed informed consent provided by the patient, or by the patient's legally authorized representative(s), as applicable. 2. documented presence of sars-cov-2 infection as per hospital routine. 3. age > 18 to < 85 years at the time of screening. 4. presence of respiratory distress, defined as: 1. pao2/fio2 < 300 mm hg and >200 mm hg or 2. respiratory rate (rr) ≥30 breaths/min or 3. spo2 < 93 percent in air at rest. note: patients given continous positive airway pressure (cpap) ventilator support are eligible for inclusion. presence of hyperinflammation defined as: 1. lymphocyte counts: - < 1000 cells/µl, in patients who have not received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count - < 1200 cells/µl, in patients who have received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count and 2. one of the following three criteria: i. ferritin > 500ng/ml ii. ldh > 300 u/l iii. d-dimers > 1000 ng/ml

inclusion criteria: 1. signed informed consent provided by the patient, or by the patient's legally authorized representative(s), as applicable. 2. documented presence of sars-cov-2 infection as per hospital routine. 3. age > 18 to < 85 years at the time of screening. 4. presence of respiratory distress, defined as: 1. pao2/fio2 < 300 mm hg and >200 mm hg or 2. respiratory rate (rr) ≥30 breaths/min or 3. spo2 < 93 percent in air at rest. note: patients given continous positive airway pressure (cpap) ventilator support are eligible for inclusion. presence of hyperinflammation defined as: 1. lymphocyte counts: - < 1000 cells/µl, in patients who have not received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count - < 1200 cells/µl, in patients who have received systemic glucocorticoids for at least 2 days prior to the assessment of the lymphocyte count and 2. one of the following three criteria: i. ferritin > 500ng/ml ii. ldh > 300 u/l iii. d-dimers > 1000 ng/ml